Company Description
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.
The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460.
It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib.
The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers.
The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.
Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1991 |
| IPO Date | Nov 4, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,524 |
| CEO | Herve Hoppenot |
Contact Details
Address: 1801 Augustine Cut-off Wilmington, Delaware 19803 United States | |
| Phone | (302) 498-6700 |
| Website | incyte.com |
Stock Details
| Ticker Symbol | INCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000879169 |
| CUSIP Number | 45337C102 |
| ISIN Number | US45337C1027 |
| Employer ID | 94-3136539 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Herve Hoppenot | Chief Executive Officer and Chairman |
| Christiana Stamoulis MBA | Executive Vice President and Chief Financial Officer |
| Dr. Barry P. Flannelly M.B.A., Pharm.D. | Executive Vice President and GM of North America |
| Dr. Steven H. Stein M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Pablo J. Cagnoni M.D., Ph.D. | President and Head of Research and Development |
| Thomas Tray | Vice President of Finance, Chief Accounting Officer and Controller |
| Michael James Morrissey | Executive Vice President and Head of Global Technical Operations |
| Sheila A. Denton | Executive Vice President, General Counsel and Corporate Secretary |
| Pamela M. Murphy | Vice President of Investor Relations and Corporate Communications |
| Paula J. Swain | Executive Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2024 | 144 | Filing |
| Jul 9, 2024 | 144 | Filing |
| Jul 3, 2024 | 8-K | Current Report |
| Jun 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 13, 2024 | SC TO-I/A | Filing |
| Jun 12, 2024 | 144 | Filing |
| Jun 11, 2024 | SC TO-I/A | Filing |
| Jun 6, 2024 | 144 | Filing |
| Jun 4, 2024 | SC TO-I/A | Filing |